On Monday, Shares of Home Depot Inc (NYSE:HD), gained 0.07% to $132.59.
The Home Depot, declared that its board of directors declared a third quarter cash dividend of 59 cents per share. The dividend is payable on December 17, 2015, to shareholders of record on the close of business on December 3, 2015. This is the 115th successive quarter the company has paid a cash dividend.
The Home Depot is the world’s largest home improvement specialty retailer, with 2,273 retail stores in all 50 states, the District of Columbia, Puerto Rico, U.S. Virgin Islands, Guam, 10 Canadian provinces and Mexico. In fiscal 2014, The Home Depot had sales of $83.2 billion and earnings of $6.3 billion. The Company employs more than 370,000 associates. The Home Depot’s stock is traded on the New York Stock Exchange (HD) and is comprised in the Dow Jones industrial average and Standard & Poor’s 500 index.
The Home Depot, Inc. operates as a home improvement retailer. It operates The Home Depot stores that sell various building materials, home improvement products, and lawn and garden products, in addition to provide installation, home maintenance, and professional service programs to do-it-yourself, do-it-for-me, and professional customers.
Shares of CVS Health Corp (NYSE:CVS), declined -0.40% to $91.56, during its last trading session.
CVS Health, declared that Repatha™ (evolocumab) from Amgen Inc. will be added as the only PCSK9 inhibitor on the CVS/caremark commercial formularies. The decision comes after a thorough evaluation of two new PCSK9 inhibitor therapies, which were approved by the FDA earlier this year.
“CVS Health is committed to providing high-quality medications for our clients and their members at the lowest possible cost. We have determined that choosing a single PCSK9 inhibitor for our commercial formularies allows us to get the best price possible for clients and preserves our commitment to deliver the best care available,” said Troyen A. Brennan, MD, MPH, executive vice president and Chief Medical Officer, CVS Health.
Per the company’s standard approach, the CVS/caremark national Pharmacy and Therapeutics (P&T) Committee carefully evaluated both of the presently available PCSK9 inhibitors and determined the drugs to be therapeutically equivalent, a decision that has been corroborated by consultation with board-certified specialists in both cardiology and endocrinology. The P&T Committee is composed of independent, external experts, counting clinical pharmacists and physicians, who evaluate the clinical appropriateness of formulary changes on a regular basis.
CVS Health Corporation, together with its auxiliaries, provides integrated pharmacy health care services in the United States. The company operates through Pharmacy Services and Retail Pharmacy segments.
Finally, Shares of Builders First Source, Inc. (NASDAQ:BLDR), ended its last trade with 3.63% gain, and closed at $13.69.
Builders Firs tSource, declared the commencement of a public offering of 7,000,000 shares of its common stock to be sold by Warburg Pincus Private Equity IX, L.P. (the “Selling Stockholder”).
The Company is not offering any shares of common stock in the offering and will not receive any proceeds from the sale of shares in this offering. In addition, none of the Company’s officers or directors are selling any shares of common stock in the offering.
The underwriter proposes to offer the shares of common stock from time to time to purchasers directly or through agents, or through brokers in brokerage transactions on the NASDAQ Global Select Market, or to dealers in negotiated transactions or in a combination of such methods of sale, at market prices prevailing at the time of sale, at prices related to such prevailing market prices or at negotiated prices, subject to its right to reject any order in whole or in part.
Deutsche Bank Securities is the underwriter for the offering. The offering will be made following an existing effective registration statement, formerly filed with the Securities and Exchange Commission (the “SEC”).
Builders First Source, Inc. manufactures and supplies structural and related building products for residential new construction primarily in the southern and eastern United States. The company offers prefabricated components, counting floor trusses, roof trusses, wall panels, stairs, and engineered wood; and window and door products, such as aluminum and vinyl windows, and pre-hung interior and exterior doors, in addition to assembles and distributes interior and exterior door units.